Myriad Genetics, Inc. announced the retirement of Jerry Lanchbury Ph.D. as chief scientific officer (CSO), after more than 19 years of distinguished service. Most recently, he drove health equity advancements such as Myriad's MyRisk Hereditary Cancer Test with RiskScore® for all ancestries.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
24.46 USD | +0.62% |
|
+0.82% | +27.80% |
06-27 | Scotiabank Initiates Myriad Genetics at Sector Outperform | MT |
06-12 | Transcript : Myriad Genetics, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 03:20 PM |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+27.80% | 2.21B | |
-11.78% | 11.24B | |
-13.76% | 7.29B | |
+29.50% | 5.57B | |
-0.19% | 5.31B | |
-19.19% | 3.68B | |
+7.62% | 2.58B | |
-65.24% | 2.33B | |
-10.48% | 2.23B | |
-19.12% | 1.57B |
- Stock Market
- Equities
- MYGN Stock
- News Myriad Genetics, Inc.
- Myriad Genetics, Inc. Announces Retirement of Chief Scientific Officer Jerry Lanchbury